Drugs / TEGTOCICLIB
TEGTOCICLIB
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07127770 | Aug → Oct 2025 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05431153 | Jun → Oct 2022 | — | Pfizer | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05262400 | Mar 2022 → Feb 2027 expected | breast cancer | Pfizer | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04553133 | Sep 2020 → Dec 2026 expected | breast cancer, ovarian cancer, small cell lung carcinoma | Pfizer | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-09-11 | Pfizer | Results Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024 pfizer.com ↗
initial data from a dose-escalation study evaluating the innovative combination of atirmociclib, a potential first-in-class CDK4-selective inhibitor, with PF-07104091, a novel CDK2-selective inhibitor, showed a manageable safety profile and encouraging efficacy in patients with heavily pretreated HR+/HER2- breast cancer. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-09-11 | Pfizer | Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024 pfizer.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TEGTOCICLIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5201870 ↗ |
| Known as | PF-07104091 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04553133 ↗ |
| Known as | Tagtociclib | ChEMBL registry synonym — accepted as the source's own label CHEMBL5201870 ↗ |
| Action | Inhibit | “Cyclin-dependent kinase-2 inhibitor” NCT07127770 ↗ |
| Modality | Small molecule | — CHEMBL5201870 ↗ |
| Route | Oral | “PF-07104091 will be administered orally” NCT04553133 ↗ |